Latest News

Chula's AICute - An Assessment Tool for Ischemic Stroke Risk

A research team from the Faculty of Medicine and Faculty of Engineering, Chulalongkorn University has jointly developed AICute, an innovative program to assess the chance of stroke caused by heart disease (Ischemic Stroke), aimed at helping hospitals that lack cardiologists to enhance the effecti...

2023-02-28 12:24 4104

Online Wholesale Platform Nihaojewelry Launches "Global Partner" Program

YIWU, China, Feb. 28, 2023 /PRNewswire/ -- Nihaojewelry, a prominent online platform forfashion jewelry wholesale , recently announced the launch of its "Global Partner" program. This initiative aims to recruit partners from various countries and regions worldwide to bring...

2023-02-28 12:14 2756

Solid performance, Golden Agri records an all-time high EBITDA of US$1.8 billion in 2022

* Golden Agri-Resources reaps the benefits of its integrated business model * Proposed final dividend of 0.991 Singapore cents per share for a total of 1.791Singapore cents per share for full year 2022, 12 percent higher than in the  previous year SINGAPORE, Feb. 28, 2023 /PRNewswire/ -- Golden...

2023-02-28 12:00 3300

Escalating Digital Transformation, ABB Presents End-to-End Integrated Solutions in the Manufacturing Industry

JAKARTA, Indonesia, Feb. 28, 2023 /PRNewswire/ -- ABB (NYSE: ABB), a global leader in providing digital solutions for manufacturing and process industries, has been continuing to make significant progress in helping businesses in its key sectors of cement, metals, mining, pulp and paper, gearless...

2023-02-28 11:21 5419

ZA Tech invests in Carro to improve and transform the auto insurance experience across Southeast Asian markets

* Cutting edge generative AI-powered, personalised and immediate: this investment enables Carro to leverage ZA Tech's suite of InsureTech solutions to distribute highly personalised insurance products and process real-time claims backed by AI capabilities * Several leading insurers, including...

2023-02-28 11:00 14140

Darwinbox Celebrates the First Edition of Its Annual '40 Under 40 Asia HR Leaders' Award 2022

SINGAPORE, Feb. 28, 2023 /PRNewswire/ -- Darwinbox launched the first edition of its40 Under 40 Asia HR Leaders 2022 annual awards, with Mercer (Knowledge Partner), to celebrate 40 exemplary HR leaders in the APAC region. The winners were announced in an online award ceremony on the 24th of Febru...

2023-02-28 10:30 5132

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hypertension (PAH) Treatment

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced positive one-year results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study at the industry's most leading American Cardiovascular Research Technologies conference (CRT 202...

2023-02-28 10:19 2547

ADA partners with MoEngage to scale Omnichannel Customer Engagement for brands using AI-powered predictive capabilities

The partnership leverages AI-driven insights to unlock deeper consumer understanding across multiple digital channels KUALA LUMPUR, Malaysia, Feb. 28, 2023 /PRNewswire/ -- Integrated growth partnerADA , have entered into an APAC-wide strategic partnership with customer eng...

2023-02-28 10:00 5555

The reimagining of Regent Hong Kong as a rare harbourfront haven by visionary designer Chi Wing Lo

HONG KONG, Feb. 28, 2023 /PRNewswire/ -- Regent Hong Kong is proud to announce the unveiling of its stunning transformation by world-renowned architect and design visionary,Chi Wing Lo as the hotel opens its room reservations from March onwards. With over 30 years of experience in architecture an...

2023-02-28 10:00 4541

"We Escaped to Japan's Paradise!" One of the World's Most Followed YouTubers is Captivated by the Charm of Japan's Southernmost, Timeless Destination: Okinawa

Check out the latest travel log of PewDiePie with 111M subscribers OKINAWA, Japan, Feb. 28, 2023 /PRNewswire/ -- PewDiePie, a popular YouTuber with more than 100 million followers worldwide, recently traveled aroundOkinawa to experience ...

2023-02-28 10:00 3127

17Sing APP looks forward to 2023, through the ambassador Aaron Yan to convey the idea that be yourself with no limits.

TAIPEI, Feb. 28, 2023 /PRNewswire/ -- 17Sing APP officially announced Aaron Yan as the brand ambassador onFebruary 14, 2023, helping young musicians pursue their dreams and step onto a bigger stage.

2023-02-28 09:47 3015

On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy

YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023'...

2023-02-28 09:16 4091

CASIO to Release Lightweight G-SHOCK Delivering Support for Multiple Sports

Equipped with Polar™ Algorithms for Training Analysis TOKYO, Feb. 28, 2023 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the release of a new addition to the sports-driven G-SQUAD line in the G-SHOCK family of shock-resistant watches. The GBD-H2000 delivers support for multiple sports...

2023-02-28 09:00 5498

Goertek unveils the first production-ready lightweight Snapdragon AR2 -based smart viewer reference design

QINGDAO, China, Feb. 27, 2023 /PRNewswire/ -- On February 27, Goertek partnered with Qualcomm Technologies, Inc. to launch a new generation of lightweight augmented reality (AR) smart viewer reference design based on the Snapdragon® AR2 Gen 1 Platform during MWC 2023. The reference design is Snap...

2023-02-28 09:00 3127

Over 90% of adults above the age of 50 carry the virus that causes shingles; yet only 3% of Singaporeans in this age group believe they are at high risk of developing the disease

GSK holds Shingles Awareness Week to educate Singaporeans about shingles and the importance of protection against it SINGAPORE, Feb. 28, 2023 /PRNewswire/ -- A GSK-sponsored Ipsos-MORI survey revealed only 3% of Singaporeans aged 50-79 years believe they are at high risk of developing shingles i...

2023-02-28 09:00 2686

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

* Entered into an acquisition deal of 3 programs YONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : ...

2023-02-28 08:53 3132

LG Innotek to lead the future device market with high-performance 2-Metal COF

* Supporting high-resolution display... Expected to increase the level of immersion for users.  * Flexibility and unbounded design with thin films * Creating differentiated customer values with 2-Metal Chip on Film (COF) highlighting 50 years of substrate business SEOUL, South Korea, Feb. 28...

2023-02-28 08:36 4973

SepPure Technologies Closes Series-A Funding Round, Raises US$12M

SINGAPORE, Feb. 28, 2023 /PRNewswire/ -- Industrial chemical membrane technology company SepPure Technologies announced today that it had closed a US$12M Series-A round led by SOSV with participation from Anji Microelectronics, RealTech Fund, Seeds Capital, EPS Ventures, and others. SepPure Techn...

2023-02-28 08:14 3011

FWD Group announces update to bond consent solicitation and publication of annual results

HONG KONG, Feb. 28, 2023 /PRNewswire/ -- FWD Limited and FWD Group Limited – consolidated subsidiaries of FWD Group Holdings Limited ("FWD Group" or "the Company") – announced updates and additional information, including full year 2022 results for FWD Group, within announcements made today to th...

2023-02-28 08:06 4066

CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma

* This supplementary new drug application was filed for the fourth indication for sugemalimab inChina, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma. If approved, sugemalimab would be the first PD-L1 monoclo...

2023-02-28 08:05 6393